FOLH1 and glioblastoma: Somatostatin receptors are overexpressed in meningiomas, while PSMA is highly expressed in the neovasculature of glioblastomas and brain metastases; both targets can be addressed using lutetium-177 (<sup>177</sup>Lu)- or actinium-225 (<sup>225</sup>Ac)-labeled radiopharmaceuticals, traditionally delivered intravenously.